Precision Medicine Series: Targeting the Vulnerabilities of Cancer

May 16-19, 2016
JW Marriott Marquis Miami
Miami, Florida

Conference Co-chairpersons
Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, Tennessee
Jeffrey Settleman, Calico Life Sciences, South San Francisco, California
Paul Workman, The Institute of Cancer Research UK, London, United Kingdom

The AACR editors are proud to present a recently curated selection of impactful journal articles on pancreatic cancer from across the AACR journal portfolio, freely available anytime, anywhere. View the collection here.

Due to the genomic changes in cancer, tumor cells have particular vulnerabilities that can be exploited through the discovery of molecules that target these differences between normal and cancer cells. In this meeting, the progress towards exploiting these vulnerabilities will be presented in the areas of targeting programmed cell death and autophagy, pathway addiction and resistance, genome instability, immune activation, epigenetics, and proteins for degradation. The talks will address progress made and future potential of therapeutic approaches exploiting oncogene addiction, non-oncogene addiction, synthetic lethality and other approaches. The talks will also address new target opportunities and key issues such as whether and how a therapeutic window can be achieved and how drug resistance mechanisms can be overcome. The conference should be of interest to anyone in the field of cancer drug discovery. Participants will learn about cancer vulnerabilities, the approaches for targeting these differences between cancer cells and normal cells, and the latest progress made in the discovery of new cancer therapeutics.

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available